A new oral drug for relapsed or refractory multiple myeloma has demonstrated promising early results in clinical trials. The treatment could help patients whose disease no longer responds to existing therapies.
How the drug works
Mezigdomide is part of a class called cereblon E3 ligase modulatory drugs, or CELMoDs. It functions similarly to lenalidomide, a widely used myeloma treatment, but binds more strongly to the cereblon protein.
Lenalidomide, often a cornerstone of myeloma therapy, attaches to cereblon to break down proteins that myeloma cells rely on. It also strengthens the immune system’s ability to target cancer cells. Mezigdomide follows the same process but with a tighter bond, which may improve its ability to eliminate remaining disease.
Brandon Blue, a hematologist/oncologist at Moffitt Cancer Center in Tampa, compared the drug’s action to a more sensitive detection system. “If the drug is sniffing out cancer so it can find and kill it, mezigdomide has a much stronger nose,” he said. “Even at very low levels of cancer, where maybe lenalidomide couldn’t detect it, this medicine can still locate it.”
Another CELMoD, iberdomide, is also being studied for myeloma. Both types of drugs help dismantle cancer-dependent proteins while enhancing immune response, offering alternatives when lenalidomide fails.
Early trial results
Data from the phase 3 SUCCESSOR-2 trial was presented at the 2026 American Society of Clinical Oncology Annual Meeting. The study tested mezigdomide combined with carfilzomib and dexamethasone (MeziKd) against carfilzomib and dexamethasone alone (Kd).
Patients on the mezigdomide combination experienced longer periods without disease progression and higher response rates.
Related: MD Anderson leads cancer hospital rankings
The treatment remains available only through clinical trials, though larger studies are underway. If approved, it would likely be used first for relapsed or refractory cases before expanding to earlier treatment stages.
Researchers emphasize that full approval depends on further evidence. Some clinicians, however, are already offering it to patients in studies. Blue noted, “I’ve given it to some of my patients, and we’ve seen fantastic results. I think it’s going to be a game changer.”
Side effects and monitoring
Mezigdomide, like other myeloma treatments, can reduce blood cell counts, especially white blood cells. This raises the risk of infections, with neutropenia—a drop in infection-fighting cells—being the most frequent issue.
“The biggest side effect is low blood counts,” Blue explained. “That can be a problem because as counts drop, infection risk rises.”
Patients are advised to monitor for fever, chills, or other infection signs and report them immediately. Doctors may prescribe preventive antibiotics or adjust dosages to reduce risks. Long-term safety and effectiveness will become clearer as more data emerges from expanded studies.
For now, mezigdomide is an experimental choice, but its early success has attracted interest. If trials continue positively, it could soon play an important role in managing a disease that often develops resistance over time.
The FDA has not yet received an approval submission, though the growing evidence suggests a potential new path for patients with limited options. Cancer patients facing additiona
Leave a Reply